CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
A

Dyslipidemia

Lipids & LipoproteinsDisease / conditionriskmodifiable
61
evidence score

Also known as: Lipid accumulation / dyslipidemia, blood lipid levels, blood lipids, changed lipid metabolism, cholesterol and other lipid levels, dyslipidaemia, dyslipidaemias, dyslipoproteinemia, fat metabolic disorders, hyperlipidaemia, hyperlipidemia, lipid disturbances

PREVENT status

Not a PREVENT input variable.

Causal support

trial evidence

Score components
lit volume: 26.3meta-analyses: 20trials: 15genetic: 0MR bonus:

References (426)

25 meta-analyses / systematic reviews

Clinical trials (222)

showing top 60
NCTTitleStatusTypeInterventions
NCT07614958A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on Top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular RiskRECRUITINGINTERVENTIONALObicetrapib 10 mg/Bempedoic Acid Placebo, Bempedoic Acid 180mg/Placebo Obicetrapib
NCT07359105A Registry-based Randomized Controlled Trial of Moderate-intensity Statin Therapy vs. Individualized Low-density Lipoprotein Cholesterol Target-based Therapy for Primary Prevention of Cardiovascular Events in Patients 70 Years of Age or Older With Type 2 Diabetes (iTARGET-Elderly Study)RECRUITINGINTERVENTIONALModerate-intensity statin monotherapy, Ezetimibe or ezetimibe-statin combination therapy
NCT07588256New Taipei City 888 Digital Medical AI Platform for the Prevention and Treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia) and Cardio-Renal-Vascular Diseases: Validation and Implementation Through Large-Scale Cluster Randomized Clinical Trials: T-888-DIGICARE-DREAMRECRUITINGINTERVENTIONALInteractive digital modules, Antihypertensive Medication Management
NCT07334834Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease: OPTIMIZE ASCVDRECRUITINGINTERVENTIONALAlgorithm- and multi-professional team-supported lipid management, Guideline-directed lipid management by usual care provider
NCT06966258Inspire HER: Inspiring the Heart and Emotions for Radical HealthRECRUITINGINTERVENTIONALInspire HER Intervention
NCT06988462Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" FoodRECRUITINGINTERVENTIONALBottarga, Comparator
NCT06603363Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CTRECRUITINGINTERVENTIONALRosuvastatin 40mg, Placebo, Coronary Computed Tomography Angiography (Coronary CTA)
NCT06980428A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels, and Participants With DyslipidemiaRECRUITINGINTERVENTIONALAZD4954, Placebo
NCT07045623Comparison of Intensive Versus Standard Care & Education for Dyslipidemia in Hypertension and Diabetes PatientsRECRUITINGINTERVENTIONALcentralized management and education group
NCT07614659Uppsala Self-Screening of Cardiovascular Health: A Randomized Controlled Trial of Home-Based Multimodal Cardiovascular Screening Versus Usual Care in Middle-Aged and Older AdultsRECRUITINGINTERVENTIONALHome-based multimodal cardiovascular screening
NCT06496243A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT StudyRECRUITINGINTERVENTIONALobicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
NCT06693934Jockey Club Precision Prevention Programme on Young Onset DiabetesRECRUITINGINTERVENTIONALRisk assessment with biogenetic and clinical test to predict diabetes risk, Oral glucose tolerance test (OGTT) and cardiovascular-kidney-metabolic (CKM) risk factors, Medication
NCT07447362Effect of a Structured Clinical and Pharmacological Management Strategy on Cardiovascular Risk Factors in Adult Patients in Routine Clinical Practice: A Pseudo-Experimental Before-and-After StudyRECRUITINGINTERVENTIONALStructured Cardiovascular Risk Management
NCT06322056Exploring Approaches With Lower Targets of Blood Pressure and Lipid for Improving Renal Outcome in Advanced Chronic Kidney DiseaseRECRUITINGINTERVENTIONALIntensive control of SBP and intensive control of LDL-C, Intensive control of SBP and standard control of LDL-C, Standard control of SBP and intensive control of LDL-C
NCT06062394Reducing Atherosclerotic Cardiovascular Disease (ASCVD) Through a Comprehensive Heart Disease Prevention Program (HDPP)RECRUITINGINTERVENTIONALPenn Med Healthy Heart Program
NCT06186037Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention : A Prospective, Multicenter, Randomized, Open-label TrialRECRUITINGINTERVENTIONALCombination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg, Mono drug group of Rosuvastatin 20 mg
NCT06055036Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health InterventionRECRUITINGINTERVENTIONALBlack Impact Intervention
NCT05845424Comparison of Efficacy and Safety of High-Intensity Statin and Ezetimibe Combination Versus StanDard carE in AsymptomatiC PatIentS wIth Presence of COroNary Artery CALCIUM (DECISION-CAL)RECRUITINGINTERVENTIONALGuideline directed statin therapy, High intensity statin plus ezetimibe therapy
NCT05457582PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter StudyRECRUITINGINTERVENTIONALPlacebo plus high-intensity statin, PCSK 9 Inhibitor plus high-intensity statin
NCT07654231Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)NOT YET RECRUITINGINTERVENTIONALLow-dose Colchicine at 0.5mg daily, Usual Care
NCT07515573A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group Clinical Trial With an Open-Label Extension to Evaluate the Effects of a Combination Dietary Supplement (Cardiol Forte) on Lipid and Glycemic Parameters in Subjects at Low Cardiovascular Risk With Suboptimal Cholesterol LevelsNOT YET RECRUITINGINTERVENTIONALCardiol Forte, Placebo
NCT07551960Design, Development and Pilot Validation of an Interventional System of the STELA Center for Preventive Medicine to Reduce Modifiable Health Risk Factors in the Adult Population (CPM-STELA)ENROLLING BY INVITATIONINTERVENTIONALSTELA Digital Preventive Medicine Platform, Comprehensive Preventive Health Assessment
NCT07441317A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of QLC7401 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia With Poorly Controlled Low-density Lipoprotein Cholesterol (LDL-C) Elevated on Optimized Lipid-lowering TherapyNOT YET RECRUITINGINTERVENTIONALQLC7401, Placebo
NCT07394517Efficacy of Phospholipid Omega-3 (Ruby-O) Versus Conventional Omega-3 on the Omega-3 Index in Patients With Mixed Dyslipidemia: A 24-Week Randomized, Double-Blind, Parallel TrialNOT YET RECRUITINGINTERVENTIONALPhospholipid Omega-3, Phospholipid Omega-3, Triglyceride Omega-3
NCT07391722A Multicentre, Randomized, Double-Blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of DNV001 Injection at Different Dosages in Patients With Primary Hypercholesterolaemia or Mixed Hyperlipidaemia and Elevated Low Density Lipoprotein Cholesterol (LDL-C) InadequateNOT YET RECRUITINGINTERVENTIONALDNV001 Injection, Placebo
NCT07151430Development and Validation of a Comprehensive Management Service Package for Older Adults With Multimorbidity: A Randomized Controlled TrialNOT YET RECRUITINGINTERVENTIONALService Package Group
NCT07198009Modulation of Bioactive Lipids in Lipid Disorders: a Pilot Study of 2-HOBA Supplementation in Individuals With Elevated Lipoprotein(a)NOT YET RECRUITINGINTERVENTIONAL2-HOBA (Hobamine)
NCT07209527Evaluation of Truway Health-Sourced Portable Diagnostic Devices for Early Detection of Chronic Conditions in Outpatient Primary Care Settings: A Prospective Interventional StudyENROLLING BY INVITATIONINTERVENTIONALTruway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
NCT07064135Impact of Prompt Medication Adjustment and Intensive Follow-up on Achieving Lipid Targets in Patients Undergoing Carotid EndarterectomyNOT YET RECRUITINGINTERVENTIONALPrompt Medication Adjustment and Intensive Follow-up, Standard Care
NCT06925100A Multicenter, Prospective, Phase IV, Interventional Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan - The CLEAR Taiwan StudyCOMPLETEDINTERVENTIONALBempedoic acid 180 mg tablet
NCT05988866Effects of a Digital Health Application (Lipodia) on LDL-cholesterol Levels in Individuals With LDL-cholesterol Levels Above Recommended Targets for Reducing Cardiovascular Risk: Randomized Controlled TrialCOMPLETEDINTERVENTIONALlipodia
NCT07421232A Phase Ⅱ Randomized, Parallel-group, Placebo-controlled, Active-controlled Trial to Assess the Efficacy, Safety of the SYH2053 Subcutaneous Injection in Participants With Primary Hypercholesterolemia or Mixed DyslipidemiaCOMPLETEDINTERVENTIONALSYH2053/placebo injection, Inclisiran (Leqvio®) 300mg
NCT06386419A Real-world, Prospective, Multi-center, Open-label, Phase 4 Clinical Study to Evaluate the Safety and Effectiveness of Subcutaneous Injection of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed DyslipidemiaCOMPLETEDINTERVENTIONALinclisiran
NCT06647238Second Time's the Charm: Evaluation of Pharmacist Interventions in Lipid Management for Secondary PreventionCOMPLETEDINTERVENTIONALPharmacist Intervention in lipid therapy
NCT06239714A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-3403 in Healthy Volunteers and Subjects With Elevated LDL-CUNKNOWNINTERVENTIONALSGB-3403, Atorvastatin, Placebo
NCT06173570A Phase IIb, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AZD0780 in Participants With DyslipidemiaCOMPLETEDINTERVENTIONALAZD0780, Placebo
NCT07295418A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Study to Evaluate the Safety and Efficacy of SAL003 Monotherapy in Participants With Hypercholesterolemia and Mixed DyslipidemiaCOMPLETEDINTERVENTIONALSAL003 140 mg, Placebo
NCT05888103A 6 Month Randomized, Double-blind, Placebo-controlled Study Followed by a 6 Month Open- Label Extension to Assess the Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein CholesterolCOMPLETEDINTERVENTIONALInclisiran, Matching Placebo for Inclisiran
NCT07278830A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of Recombinant Fully Human Anti-PCSK9 Monoclonal Antibody Injection (SAL003) Combined With Atorvastatin in Subjects With Hypercholesterolemia and Mixed DyslipidemiaCOMPLETEDINTERVENTIONALSAL003 140mg+Atorvastatin, SAL003 420mg+Atorvastatin, Placebo 140mg+Atorvastatin
NCT05820295Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care CoordinationCOMPLETEDINTERVENTIONALCare coordination delivered based on perceived need, Care coordination delivered based on usual care (e.g. discharge from hospital)
NCT05787002An Open-label, 2-Period, 2-Sequence Cross-over Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin in Healthy ParticipantsCOMPLETEDINTERVENTIONALAZD0780, Rosuvastatin
NCT05579418The Safety and Long-Term Clinical Benefit of PCSK9i in Addition to Statin Therapy in Patients With ST-Segment Elevation Myocardial Infarction. A Randomized, Open Label Study.UNKNOWNINTERVENTIONALEvolocumab
NCT06115213Mass Screening of the Population of the North Kynouria Municipality in Arcadia, Greece for the Detection of Cardiovascular and Stroke Risk FactorsUNKNOWNINTERVENTIONALPatient counselling
NCT04922424Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans MenWITHDRAWNINTERVENTIONALAtorvastatin, placebo
NCT05624658Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With Acute Coronary Syndrome, a Prospective, Open-label, Randomized, Single-center StudyUNKNOWNINTERVENTIONALCombined Lipid-lowering Therapy
NCT04977583The Effect of Screening and Referral for Social Determinants of Health on Veterans' OutcomesCOMPLETEDINTERVENTIONALUnmet Need Screening, Unmet Need Referral - Resource Sheet, Unmet Need Referral Assistance
NCT05266586A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination With Ezetimibe 10 mg Daily as an Adjunct to High-Intensity Statin Therapy: The ROSE 2 StudyCOMPLETEDINTERVENTIONALObicetrapib, Ezetimibe 10mg, Obicetrapib placebo
NCT05087823Measurements of Lipoproteins, Apolipoproteins, and Lipids in Three Separate Oral Challenges - Fat, Sugar, and Mixed Test MealsCOMPLETEDINTERVENTIONALLipid Challenge, Glucose Challenge, Mixed Meal Challenge
NCT05537948Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant PatientsACTIVE NOT RECRUITINGINTERVENTIONALPitavastatin, PCSK9 inhibitor
NCT05806723Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic MenCOMPLETEDINTERVENTIONALAtorvastatin 40 Mg Oral Tablet
NCT04774003A Placebo-controlled, Participant, Investigator and Sponsor Blinded, Randomized Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Inclisiran Treatment Given as Single Subcutaneous Injection in Chinese Participants With Elevated Low-density Lipoprotein Cholesterol (LDL-C) Despite Treatment With LDL-C Lowering Therapies (ORION-14)COMPLETEDINTERVENTIONAL100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), Placebo, 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)
NCT04608474Lipid Management in Renal Transplant Recipients: a Pilot Study Evaluating the Use of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitor Evolocumab.COMPLETEDINTERVENTIONALEvolocumab
NCT04516291A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF-07285557) in Statin-Treated Participants With DyslipidemiaCOMPLETEDINTERVENTIONALVupanorsen, Placebo
NCT03748420A Team-Based and Technology-Driven Adherence Intervention to Improve Chronic Disease OutcomesCOMPLETEDINTERVENTIONALAdherence Intervention
NCT04223557Non-invasive Focused Power Ultrasound Mediated Inferior Perirenal Fat Ablation for Lowering Serum CholesterolCOMPLETEDINTERVENTIONALfocused power ultrasound treatment, Sham treatment
NCT03750760Early Alirocumab to Reduce LDL-C in Myocardial InfarctionWITHDRAWNINTERVENTIONALAlirocumab, Atorvastatin 80mg, Ezetimibe 10mg
NCT04097171The Effect of Diet Composition on Performance, Energy Expenditure, Blood Lipids and Lipoproteins, and Cognitive Function and Mood States in Highly Trained CyclistsCOMPLETEDINTERVENTIONALDiet
NCT04067297Using Big Data to Conduct Innovative Cardiovascular Clinical Trials: The Community Heart Outcomes Improvement and Cholesterol Education Study (CHOICES)ACTIVE NOT RECRUITINGINTERVENTIONALLipid management toolbox
NCT04073134Cholesterol Reduction With Evolocumab and Coronary MicrovascuLar Function and Coronary Flow: The CHORAL Flow StudyTERMINATEDINTERVENTIONALEvolocumab, Placebo
NCT04074551A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and DyslipidemiaCOMPLETEDINTERVENTIONALHCP1701, Losartan, Amlodipine

Genetic associations (0)

None linked.